CGN

Summary

CGN (cingulin, HGNC:17429) is a protein-coding gene on chromosome 1q21.3, encoding Cingulin (Q9P2M7). Probably plays a role in the formation and regulation of the tight junction (TJ) paracellular permeability barrier.

Enables cadherin binding activity. Predicted to be involved in microtubule cytoskeleton organization. Predicted to act upstream of or within bicellular tight junction assembly and epithelial cell morphogenesis. Located in bicellular tight junction and plasma membrane.

Source: NCBI Gene 57530 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 223 total
• MANE Select transcript: NM_020770

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17429
Approved symbol	CGN
Name	cingulin
Location	1q21.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1319
Ensembl gene	ENSG00000143375
Ensembl biotype	protein_coding
OMIM	609473
Entrez	57530

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 14 protein_coding, 3 retained_intron

ENST00000271636, ENST00000416743, ENST00000427934, ENST00000464886, ENST00000467998, ENST00000473377, ENST00000502442, ENST00000505188, ENST00000879038, ENST00000879039, ENST00000879040, ENST00000879041, ENST00000928061, ENST00000928062, ENST00000928063, ENST00000928064, ENST00000962862

RefSeq mRNA: 1 — MANE Select: NM_020770 NM_020770

CCDS: CCDS999

Canonical transcript exons

ENST00000271636 — 21 exons

Exon	Start	End
ENSE00000959670	151520166	151520266
ENSE00000959671	151520414	151520483
ENSE00000959672	151520596	151520691
ENSE00000959674	151524226	151524358
ENSE00000959675	151524674	151524886
ENSE00000959676	151525642	151525790
ENSE00000959680	151530489	151530746
ENSE00000959681	151532402	151532572
ENSE00000959682	151533975	151534136
ENSE00000959683	151535042	151535131
ENSE00001436343	151529350	151529559
ENSE00001436384	151529909	151530115
ENSE00001596393	151511387	151511515
ENSE00003463739	151536237	151536345
ENSE00003501439	151536730	151536893
ENSE00003562037	151535780	151535898
ENSE00003568370	151526975	151527107
ENSE00003604275	151535600	151535683
ENSE00003653528	151537205	151538692
ENSE00003786637	151523434	151523561
ENSE00003796769	151518506	151519392

Expression profiles

Bgee: expression breadth ubiquitous, 215 present calls, max score 98.79.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5339 / max 63.5436, expressed in 622 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
5229	1.6297	525
5228	0.6394	313
5230	0.2648	158

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	98.79	gold quality
ileal mucosa	UBERON:0000331	97.68	gold quality
mucosa of transverse colon	UBERON:0004991	97.29	gold quality
right uterine tube	UBERON:0001302	95.75	gold quality
body of pancreas	UBERON:0001150	95.29	gold quality
rectum	UBERON:0001052	94.91	gold quality
right lobe of liver	UBERON:0001114	94.80	gold quality
metanephros cortex	UBERON:0010533	93.56	gold quality
duodenum	UBERON:0002114	93.25	gold quality
upper lobe of left lung	UBERON:0008952	92.80	gold quality
right lung	UBERON:0002167	92.29	gold quality
lower esophagus mucosa	UBERON:0035834	92.26	gold quality
sural nerve	UBERON:0015488	92.17	gold quality
secondary oocyte	CL:0000655	92.01	gold quality
pancreas	UBERON:0001264	91.95	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	91.95	gold quality
upper lobe of lung	UBERON:0008948	91.91	gold quality
skin of leg	UBERON:0001511	91.77	gold quality
jejunal mucosa	UBERON:0000399	91.51	gold quality
minor salivary gland	UBERON:0001830	91.49	gold quality
liver	UBERON:0002107	91.18	gold quality
oviduct epithelium	UBERON:0004804	91.13	gold quality
skin of abdomen	UBERON:0001416	90.98	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.84	gold quality
cerebellar hemisphere	UBERON:0002245	90.33	gold quality
cerebellar cortex	UBERON:0002129	90.10	gold quality
transverse colon	UBERON:0001157	89.76	gold quality
oocyte	CL:0000023	89.50	gold quality
colonic mucosa	UBERON:0000317	89.50	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.42	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

103 targeting CGN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-3919	99.87	69.45	2489

Literature-anchored findings (GeneRIF, showing 10)

• Cingulin (KIAA1319 protein) is localized in the cytoplasmic domain of vertebrate epithelial tight junctions, and it interacts with other tight junction proteins such as ZO-1, and with the actomyosin cytoskeleton. (PMID:11042084)
• Results indicate that cells underwent EMT exhibited overactive TGFbeta signaling and loss of expression of the CDH1, CGN, CLDN4, and KLK10 genes as a result of hypermethylation of their corresponding promoter regions. (PMID:20086175)
• Co-imunoprecipitation and confocal microscopy experiments also revealed the tight junction protein cingulin as a new interacting partner of Ubn-1 (PMID:22245583)
• MgcRacGAP colocalizes with CGN and CGNL1 at TJs and forms a complex and interacts directly in vitro with CGN and CGNL1. (PMID:24807907)
• Cingulin modulates barrier function in endothelium. (PMID:26821949)
• Down-regulation of Cingulin Augments Thrombin-induced Endothelial Barrier Disruption. (PMID:27590342)
• Phosphorylated cingulin localises GEF-H1 at tight junctions to protect vascular barriers in blood endothelial cells. (PMID:34345888)
• miR-1270 enhances the proliferation, migration, and invasion of osteosarcoma via targeting cingulin. (PMID:34873899)
• Cingulin regulates hair cell cuticular plate morphology and is required for hearing in human and mouse. (PMID:37691516)
• The Roles and Regulatory Mechanisms of Tight Junction Protein Cingulin and Transcription Factor Forkhead Box Protein O1 in Human Lung Adenocarcinoma A549 Cells and Normal Lung Epithelial Cells. (PMID:38338691)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cgna	ENSDARG00000055607
danio_rerio	cgnb	ENSDARG00000058690
mus_musculus	Cgn	ENSMUSG00000068876

Paralogs (44): MYH13 (ENSG00000006788), MYO16 (ENSG00000041515), MYO9A (ENSG00000066933), MYO3B (ENSG00000071909), MYH7B (ENSG00000078814), MYO15A (ENSG00000091536), MYH7 (ENSG00000092054), MYO3A (ENSG00000095777), MYO9B (ENSG00000099331), MYH9 (ENSG00000100345), MYH14 (ENSG00000105357), MYH1 (ENSG00000109061), MYH3 (ENSG00000109063), MYH2 (ENSG00000125414), MYO1B (ENSG00000128641), MYO5C (ENSG00000128833), CGNL1 (ENSG00000128849), MYH8 (ENSG00000133020), MYH10 (ENSG00000133026), MYH11 (ENSG00000133392), MYO18B (ENSG00000133454), CCDC102A (ENSG00000135736), MYO1G (ENSG00000136286), MYO7A (ENSG00000137474), MYO1F (ENSG00000142347), TMF1 (ENSG00000144747), MYH15 (ENSG00000144821), MYO10 (ENSG00000145555), CCDC102B (ENSG00000150636), MYO1E (ENSG00000157483), CCDC158 (ENSG00000163749), MYO1A (ENSG00000166866), MYO5B (ENSG00000167306), MYO7B (ENSG00000169994), MYO1H (ENSG00000174527), MYO1D (ENSG00000176658), MYO18A (ENSG00000196535), MYO6 (ENSG00000196586), MYO5A (ENSG00000197535), MYH6 (ENSG00000197616)

Protein

Protein identifiers

Cingulin — Q9P2M7 (reviewed: Q9P2M7)

All UniProt accessions (4): Q9P2M7, A2A3M4, A6PVU7, H0Y4A8

UniProt curated annotations — full annotation on UniProt →

Function. Probably plays a role in the formation and regulation of the tight junction (TJ) paracellular permeability barrier.

Subunit / interactions. Homodimer. Interacts with TJP1/ZO1. Interacts with SPEF1.

Subcellular location. Cell junction. Tight junction.

Tissue specificity. Localized on the cytoplasmic face of tight junctions of polarized epithelia and some endothelia. Expressed in pancreas, kidney, liver and lung, but not in skeletal muscle, placenta, brain or heart.

Domain organisation. Deletion of the TJP1/ZO1 interaction motif (ZIM) decreases but does not abolish colocalization with TJP1/ZO1.

Miscellaneous. May be due to an intron retention.

Similarity. Belongs to the cingulin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9P2M7-1	1	yes
Q9P2M7-2	2

RefSeq proteins (1): NP_065821* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002928	Myosin_tail	Domain

Pfam: PF01576

UniProt features (35 total): modified residue 18, region of interest 8, compositionally biased region 3, splice variant 2, chain 1, short sequence motif 1, sequence variant 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P2M7-F1	70.44	0.39

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (18): 95, 96, 135, 137, 140, 155, 165, 214, 217, 258, 276, 338, 351, 579, 712, 1175, 1176, 1182

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)

MSigDB gene sets: 144 (showing top): REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX, ATACCTC_MIR202, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, KEGG_TIGHT_JUNCTION, TGACCTY_ERR1_Q2, CHX10_01, USF_C, NFKB_Q6, GTGCCTT_MIR506, TCF4_Q5, CEBP_Q2, NKX62_Q2, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, WANG_LMO4_TARGETS_DN, USF_01

GO Biological Process (1): microtubule cytoskeleton organization (GO:0000226)

GO Molecular Function (4): actin binding (GO:0003779), microtubule binding (GO:0008017), cadherin binding (GO:0045296), protein binding (GO:0005515)

GO Cellular Component (5): plasma membrane (GO:0005886), bicellular tight junction (GO:0005923), myosin complex (GO:0016459), cell junction (GO:0030054), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by TGF-beta Receptor Complex	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoskeleton organization	1
microtubule-based process	1
cytoskeletal protein binding	1
tubulin binding	1
cell adhesion molecule binding	1
binding	1
membrane	1
cell periphery	1
apical junction complex	1
tight junction	1
actin cytoskeleton	1
protein-containing complex	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

975 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CGN	TJP2	Q9UDY2	999
CGN	TJP1	Q07157	998
CGN	TJP3	O95049	997
CGN	OCLN	Q16625	995
CGN	MARVELD2	Q8N4S9	987
CGN	AFDN	P55196	975
CGN	F11R	Q9Y624	963
CGN	ARHGEF2	Q92974	947
CGN	A0A087WZG4	A0A087WZG4	923
CGN	ARHGEF18	Q6ZSZ5	923
CGN	RACGAP1	Q9H0H5	919
CGN	SYMPK	Q92797	854
CGN	MPDZ	O75970	854
CGN	ASH1L	Q9NR48	847
CGN	PLEKHA7	Q6IQ23	783

IntAct

292 interactions, top by confidence:

A	B	Type	Score
YWHAH	ABLIM1	psi-mi:“MI:0914”(association)	0.800
CGN	YWHAQ	psi-mi:“MI:0914”(association)	0.710
CGN	YWHAE	psi-mi:“MI:0914”(association)	0.710
YWHAG	BLTP3B	psi-mi:“MI:2364”(proximity)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAB	BLTP3B	psi-mi:“MI:2364”(proximity)	0.610
YWHAH	BLTP3B	psi-mi:“MI:2364”(proximity)	0.570
YWHAG	SHTN1	psi-mi:“MI:0914”(association)	0.560
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
YWHAQ	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
L1TD1	PARP1	psi-mi:“MI:0914”(association)	0.460
ESR2	FBLL1	psi-mi:“MI:0914”(association)	0.460
CGN	SNX27	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	RHPN1	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	PATJ	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	PDZD2	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	TAMALIN	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	APBA3	psi-mi:“MI:0407”(direct interaction)	0.440
AHNAK	CGN	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	APBA1	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	APBA2	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	ARHGEF11	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	CARD11	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	CASK	psi-mi:“MI:0407”(direct interaction)	0.440
CGN	WHRN	psi-mi:“MI:0407”(direct interaction)	0.440
WHRN	CGN	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (198): CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Affinity Capture-MS), CGN (Proximity Label-MS), CGN (Proximity Label-MS), YWHAZ (Affinity Capture-MS)

ESM2 similar proteins: A0A2R8QCI3, A0JMK8, A3KGV1, A7YH32, A9X1A5, B0KWC9, B6MFW3, B8JK76, G5E861, G9G127, O35550, O35551, P59242, P85120, Q15276, Q3V6T2, Q502I3, Q5BJF6, Q5RG45, Q5SNZ0, Q5TZ80, Q5ZJ27, Q5ZKK5, Q66GS9, Q66KE8, Q6AYX5, Q6DIX6, Q6NRB0, Q6P402, Q6P5D4, Q6PGZ0, Q6VGS5, Q6ZU80, Q7TMK6, Q80UF4, Q80YF0, Q80YT7, Q86SQ7, Q8BIL5, Q8CJ99

Diamond homologs: A7YH32, A9X1A5, B0KWC9, B1MTG4, B1WB65, B3EX63, P14105, P59242, Q0VF96, Q1L8T5, Q6AW69, Q99105, Q9P2M7, Q9PTD7, P35579, Q258K2, P10587, P35580, P35749, P12844, O08638, P35748, Q27991, Q61879, Q62812, Q63862, Q6URW6, Q7Z406, Q8VDD5, Q99323, Q9JLT0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 179 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	9	49.1×	2e-11
Activation of BAD and translocation to mitochondria	7	43.3×	9e-09
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	38.2×	2e-08
Activation of BH3-only proteins	7	28.3×	2e-07
RHO GTPases activate PKNs	10	25.8×	9e-10
Intrinsic Pathway for Apoptosis	7	16.7×	7e-06
FOXO-mediated transcription	5	13.7×	6e-04
Neurexins and neuroligins	8	12.8×	7e-06

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	6	20.9×	2e-04
regulation of postsynaptic membrane neurotransmitter receptor levels	7	20.8×	4e-05
protein targeting	6	13.2×	1e-03
negative regulation of translation	7	8.2×	4e-03
cellular response to insulin stimulus	7	7.1×	7e-03
intracellular protein localization	9	5.6×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

223 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	193
Likely benign	11
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2777 predictions. Top by Δscore:

Variant	Effect	Δscore
1:151511513:AGGGT:A	donor_loss	1.0000
1:151511514:GG:G	donor_gain	1.0000
1:151511515:GG:G	donor_gain	1.0000
1:151511516:G:C	donor_loss	1.0000
1:151511516:G:GG	donor_gain	1.0000
1:151518501:TCTA:T	acceptor_loss	1.0000
1:151518502:CTAG:C	acceptor_loss	1.0000
1:151518503:TA:T	acceptor_loss	1.0000
1:151518504:A:AG	acceptor_gain	1.0000
1:151518504:AGG:A	acceptor_loss	1.0000
1:151518505:G:A	acceptor_loss	1.0000
1:151518505:G:GG	acceptor_gain	1.0000
1:151520165:GTTC:G	acceptor_gain	1.0000
1:151520262:GAGGG:G	donor_gain	1.0000
1:151520264:GGG:G	donor_gain	1.0000
1:151520264:GGGGT:G	donor_loss	1.0000
1:151520265:GGG:G	donor_gain	1.0000
1:151520266:GGTG:G	donor_loss	1.0000
1:151520267:GTGA:G	donor_loss	1.0000
1:151520268:T:G	donor_loss	1.0000
1:151520412:A:AG	acceptor_gain	1.0000
1:151520413:G:GG	acceptor_gain	1.0000
1:151520413:GA:G	acceptor_gain	1.0000
1:151520413:GAA:G	acceptor_gain	1.0000
1:151520594:AGAT:A	acceptor_gain	1.0000
1:151520595:GATG:G	acceptor_gain	1.0000
1:151523431:CA:C	acceptor_loss	1.0000
1:151523432:A:AC	acceptor_loss	1.0000
1:151523432:A:AG	acceptor_gain	1.0000
1:151523433:G:GG	acceptor_gain	1.0000

AlphaMissense

7764 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000081141 (1:151531089 C>T), RS1000092828 (1:151512989 G>A), RS1000264401 (1:151516891 G>A), RS1000361976 (1:151509998 TAA>T,TA,TAAA,TAAAA), RS1000396748 (1:151509883 TAAA>T,TAA,TAAAA), RS1000455130 (1:151513191 C>A), RS1000503726 (1:151513538 C>T), RS1000541504 (1:151536936 G>A), RS1000594811 (1:151529326 A>G), RS1000807834 (1:151523245 A>G), RS1000947518 (1:151527234 G>A), RS1000957308 (1:151527575 G>A), RS1001086290 (1:151519843 A>G), RS1001149383 (1:151532878 C>T), RS1001309705 (1:151526461 C>A)

Disease associations

OMIM: gene MIM:609473 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005951_38	Body mass index	4.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, decreases methylation, affects cotreatment	6
Estradiol	decreases expression, increases reaction, affects binding, increases expression, affects cotreatment	4
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment, decreases expression	3
Benzo(a)pyrene	decreases expression, decreases methylation	3
Tobacco Smoke Pollution	affects expression, decreases expression, increases expression	3
Cyclosporine	decreases expression	3
Particulate Matter	decreases expression, increases abundance, increases expression	3
methylmercuric chloride	affects cotreatment, increases expression	2
Air Pollutants	increases abundance, increases expression, decreases expression	2
Phenobarbital	affects expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Aflatoxin B1	affects expression, decreases expression, increases methylation	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
propionaldehyde	increases expression	1
bisphenol A	decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
afimoxifene	decreases expression, decreases reaction	1
butyraldehyde	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
pentanal	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide	decreases expression	1
bisphenol S	decreases methylation	1
jinfukang	decreases expression, affects cotreatment	1
LDN 193189	decreases expression, affects cotreatment	1
Rosiglitazone	decreases expression	1
Temozolomide	increases expression	1
Zoledronic Acid	decreases expression	1
Acetaminophen	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.